BRAF and neoplasm: A phase 2 trial on patients with refractory/progressing LGG (NF1 patients and patients who carried KIA11549-BRAF fusion) and treated with trametinib, will investigate the molecular biological mechanisms that drive tumor development and progression, and the involvement of these mechanisms in resistance to therapy (100).